Molecular Partners AG

Ticker: MOLN

Class Period Start: 06/16/2021

Class Period End: 04/26/2022

Registration Deadline: 09/12/2022

A securities class action lawsuit has been filed in the USDC, S.D.N.Y. against Molecular Partners AG (MOLN) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (b) Molecular Partners securities between June 16, 2021 through April 26, 2022. 

According to the Complaint, the IPO documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, the complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the IPO documents and defendants made false and/or misleading statements and/or failed to disclose that:

  • ensovibep was less effective at treating COVID-19 than defendants had led investors to believe;
  • accordingly, the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”);
  • waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep;
  • as a product candidate, MP0310 (AMG 506), in development for the treatment of certain types of cancer,  was less attractive to Amgen Inc. (“Amgen”) than defendants had led investors to believe;
  • accordingly, there was a significant likelihood that Amgen would return global rights of MP0310 to Molecular Partners;
  • as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and
  • as a result, the IPO documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Purchases

Sales

Please Note

Neither the submission to nor the receipt of information by Lowey Dannenberg or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* Indicates a required field.

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.